Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based EPIRUS Biopharmaceuticals has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm (Livzon), a Chinese biotechnology firm focused on the development, manufacture, and sale of antibody-based drugs.
Subscribe to our email newsletter
Prior to becoming a public company, Livzon was a principal investor in the $36m private financing round EPIRUS that closed in April 2014.
EPIRUS’ Remicade biosimilar BOW015 (infliximab) is the first collaboration product and it was recently approved in India.
As part of the deal, the two firms will jointly work to develop, manufacture and commercialize up to five biosimilar products. Livzon will conduct any additional development work needed for the approval of BOW015 in China and Taiwan.
The company will also serve as the preferred supplier of BOW015 in these territories, following a transfer of EPIRUS’ SCALE manufacturing platform.
Livzon will be also responsible for all commercialization activities in its territories.
EPIRUS president and CEO Amit Munshi said the company has established a significant collaboration with a strong partner in a compelling market.
"This agreement also reinforces the importance of our SCALE™ manufacturing platform for in market production globally," Munshi said.